ReviewLiver cancer2015
Yttrium-90 microsphere radioembolization for hepatocellular carcinoma.
Review in Liver cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma and Combination Strategies.Maedica · 2026Review
- MRI radiomics andBMC cancer · 2026Article
- Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy.Liver research (Beijing, China) · 2026Review
- Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy.Biomimetics (Basel, Switzerland) · 2025Review
- Advances and Emerging Techniques in Y-90 Radioembolization for Hepatocellular Carcinoma.Cancers · 2025Review
- Yttrium-Enriched Phosphate Glass-Ceramic Microspheres for Bone Cancer Radiotherapy Treatment.ACS omega · 2024Article
- [Application of drug delivery microspheres in cancer therapy].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Review
- Hepatocellular Carcinoma: Surgical Management and Evolving Therapies.Cancer treatment and research · 2024Review
- Applications of Yttrium-90 (OncoTargets and therapy · 2024Review
- Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion.European radiology · 2023Review
- Imaging evaluation following transarterial radioembolization with yttrium-90 microspheres downstaging hepatocellular carcinoma: the first case in China.Quantitative imaging in medicine and surgery · 2023Article
- The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences.Journal of the National Cancer Center · 2022Review
- The inhibiting effect of alpha-based TARE on embolized vessels and neovascularization.Frontiers in bioengineering and biotechnology · 2022Article
- Clinical perspectives for the use of total body PET/CT.European journal of nuclear medicine and molecular imaging · 2021Article
- Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission.Journal of pain and symptom management · 2021Article
- Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience.Diagnostics (Basel, Switzerland) · 2021Article
- Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization withCancers · 2020Review
- Microwave Ablation in Intermediate Hepatocellular Carcinoma in Cirrhosis: An Italian Multicenter Prospective Study.Journal of clinical and translational hepatology · 2018Article
- Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).Liver cancer · 2018Article
- Gastrodoudenal Embolization: Indications, Technical Pearls, and Outcomes.Journal of clinical medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yttrium-90 (Y90) radioembolization is an emerging strategy to treat liver malignancies, and clinical data supporting its use have accumulated in recent years. Y90-radioembolization has shown clinical effectiveness in intermediate and advanced hepatocellular carcinoma, with a favorable safety profile. Retrospective data show similar levels of effectiveness to transarterial chemoembolization in intermediate hepatocellular carcinoma, with some evidence of better tolerance. While phase 3 studies comparing Y90-radioembolization to chemoembolization in intermediate hepatocellular carcinoma would be difficult to conduct, studies comparing or combining Y90-radioembolization with sorafenib are under way. Questions also remain about the most suitable modalities for defining the dose to administer. Phase 3 studies are under way to clarify the place of Y90-radioembolization in the algorithm of HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.